Clinical Trial Update: Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease

View source ↗

Summary

Expanded Access update for Amicus Therapeutics' ATB200/AT2221 in Pompe disease. The document notes that access is AVAILABLE under the program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• ATB200/AT2221

Snippet

Sponsor: Amicus Therapeutics | Conditions: Pompe Disease | Status: AVAILABLE